CN102105174B - 对金属蛋白酶选择性的诊断剂 - Google Patents
对金属蛋白酶选择性的诊断剂 Download PDFInfo
- Publication number
- CN102105174B CN102105174B CN200980128435.1A CN200980128435A CN102105174B CN 102105174 B CN102105174 B CN 102105174B CN 200980128435 A CN200980128435 A CN 200980128435A CN 102105174 B CN102105174 B CN 102105174B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- group
- imaging
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 O=*OCc1ccccc1 Chemical compound O=*OCc1ccccc1 0.000 description 9
- JZALSOUNNLOSMW-UHFFFAOYSA-O CC[N+](c(cc1)c(C2(C)C)c3c1c([S](C)(O)(=O)=O)cc(S(O)(=O)=O)c3)=C2C=CC=CC=C(C1(C)C)N(CCCCCC(N2CCN(CCOCCON(CC(ON)=O)S(=O)=O)CC2)=O)c(cc2)c1c1c2c(C)cc(S(O)(=O)=O)c1 Chemical compound CC[N+](c(cc1)c(C2(C)C)c3c1c([S](C)(O)(=O)=O)cc(S(O)(=O)=O)c3)=C2C=CC=CC=C(C1(C)C)N(CCCCCC(N2CCN(CCOCCON(CC(ON)=O)S(=O)=O)CC2)=O)c(cc2)c1c1c2c(C)cc(S(O)(=O)=O)c1 JZALSOUNNLOSMW-UHFFFAOYSA-O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
- A61K49/105—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA the metal complex being Gd-DTPA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasonic imaging preparations
- A61K49/221—Echographic preparations; Ultrasonic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Radiology & Medical Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Optics & Photonics (AREA)
- Acoustics & Sound (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08160856.4 | 2008-07-22 | ||
| EP08160856A EP2147684A1 (en) | 2008-07-22 | 2008-07-22 | Diagnostic Agents Selective Against Metalloproteases |
| PCT/EP2009/059338 WO2010010079A1 (en) | 2008-07-22 | 2009-07-21 | Diagnostic agents selective against metalloproteases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102105174A CN102105174A (zh) | 2011-06-22 |
| CN102105174B true CN102105174B (zh) | 2014-07-02 |
Family
ID=39737623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200980128435.1A Expired - Fee Related CN102105174B (zh) | 2008-07-22 | 2009-07-21 | 对金属蛋白酶选择性的诊断剂 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9480758B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP2147684A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP5619740B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN102105174B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2010010079A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3003395B1 (en) * | 2013-05-30 | 2019-07-17 | Bracco Imaging S.p.A | Fluorescent solid lipid nanoparticles composition and preparation thereof |
| WO2018204872A2 (en) | 2017-05-05 | 2018-11-08 | Fusion Pharmaceuticals Inc. | Igf-1r monoclonal antibodies and uses thereof |
| US10093741B1 (en) | 2017-05-05 | 2018-10-09 | Fusion Pharmaceuticals Inc. | IGF-1R monoclonal antibodies and uses thereof |
| AU2018261888B2 (en) | 2017-05-05 | 2022-06-30 | Centre For Probe Development And Commercialization | Pharmacokinetic enhancements of bifunctional chelates and uses thereof |
| CN117957214A (zh) * | 2021-05-13 | 2024-04-30 | 总医院公司 | 用于醛类的体内检测的分子探针 |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998039313A1 (en) * | 1998-03-04 | 1998-09-11 | Monsanto Company | Thioaryl sulfonamide hydroxamic acid compounds |
| CN1207734A (zh) * | 1995-12-08 | 1999-02-10 | 阿格罗尼制药公司 | 金属蛋白酶抑制剂,含有它们的药物组合物和其药物用途,其制备方法和中间体 |
| CN1214041A (zh) * | 1996-01-23 | 1999-04-14 | 盐野义制药株式会社 | 磺化的氨基酸衍生物及含有它的金属蛋白酶抑制剂 |
| WO1999042433A1 (en) * | 1998-02-18 | 1999-08-26 | Inha University Foundation | Process for nitration of aromatic compounds using a non-acid type nitration process |
| US5985900A (en) * | 1997-04-01 | 1999-11-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| WO2003080042A1 (en) * | 2002-03-27 | 2003-10-02 | Shionogi & Co., Ltd. | Decomposition inhibitor for extracellular matrix of cartilage |
| CN1450915A (zh) * | 2000-02-15 | 2003-10-22 | 布里斯托尔-迈尔斯斯奎布药品公司 | 作为诊断剂中靶组分的基质金属蛋白酶抑制剂 |
| CN1747749A (zh) * | 2003-02-10 | 2006-03-15 | 通用电气健康护理有限公司 | 具有mmp抑制活性的诊断造影剂 |
| CN1901894A (zh) * | 2003-11-14 | 2007-01-24 | 通用电气健康护理有限公司 | 抑制剂成像剂 |
| CN1913880A (zh) * | 2003-12-04 | 2007-02-14 | 惠氏公司 | 治疗adamts-5相关疾病的方法 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4180646A (en) | 1975-01-28 | 1979-12-25 | Alza Corporation | Novel orthoester polymers and orthocarbonate polymers |
| US4131648A (en) | 1975-01-28 | 1978-12-26 | Alza Corporation | Structured orthoester and orthocarbonate drug delivery devices |
| US4093709A (en) | 1975-01-28 | 1978-06-06 | Alza Corporation | Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates) |
| US5362476A (en) | 1984-10-18 | 1994-11-08 | Board Of Regents, The University Of Texas System | Alkyl phosphonate polyazamacrocyclic cheates for MRI |
| MX174467B (es) | 1986-01-23 | 1994-05-17 | Squibb & Sons Inc | 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos |
| IT1213029B (it) | 1986-01-30 | 1989-12-07 | Bracco Ind Chimica Spa | Chelati di ioni metallici paramagnetici. |
| US5021556A (en) | 1987-07-22 | 1991-06-04 | Neorx Corporation | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides |
| US5075099A (en) | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5914095A (en) | 1989-04-07 | 1999-06-22 | Salutar, Inc. | Polychelants containg amide bonds |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| US5118797A (en) | 1989-08-28 | 1992-06-02 | E. R. Squibb & Sons, Inc. | Rhenium tris dioxime complexes |
| CA2034042C (en) | 1990-01-18 | 1999-08-17 | Adrian D. Nunn | Boronic acid adducts of rhenium dioxime and technetium-99m dioxime complexes containing a biochemically active group |
| US5578292A (en) | 1991-11-20 | 1996-11-26 | Bracco International B.V. | Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof |
| US5183653A (en) | 1990-04-13 | 1993-02-02 | E. R. Squibb & Sons, Inc. | Boronic acid adducts of metal dioxime complexes useful in labelling proteins and other amine-containing compounds |
| AU636481B2 (en) | 1990-05-18 | 1993-04-29 | Bracco International B.V. | Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography |
| US5367080A (en) | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
| US5965107A (en) | 1992-03-13 | 1999-10-12 | Diatide, Inc. | Technetium-99m labeled peptides for imaging |
| JP2774378B2 (ja) | 1991-02-08 | 1998-07-09 | ダイアテク,インコーポレイテッド | 映像用テクネチウム−99m標識化ポリペプチド |
| US5849261A (en) | 1991-02-08 | 1998-12-15 | Diatide, Inc. | Radiolabeled vasoactive intestinal peptides for diagnosis and therapy |
| US5808091A (en) | 1991-10-29 | 1998-09-15 | Bracco International B.V. | Rhenium and technetium complexes containing a hypoxia localizing moiety |
| IL104084A (en) | 1992-01-24 | 1996-09-12 | Bracco Int Bv | Long-lasting aqueous suspensions of pressure-resistant gas-filled microvesicles their preparation and contrast agents consisting of them |
| US5608110A (en) | 1993-06-15 | 1997-03-04 | Bracco International B.V. | Heteroatom-bearing ligands and metal complexes thereof |
| AU7261994A (en) | 1993-07-19 | 1995-02-20 | Resolution Pharmaceuticals Inc. | Hydrazino-type radionuclide chelators having an n3s configuration |
| US5409689A (en) | 1993-08-13 | 1995-04-25 | Concat, Ltd. | MRI image enhancement using complexes of paramagnetic cations and amine ligands containing a mixture of phosphonate and non-phosphonate pendant arms |
| US5574140A (en) | 1993-09-03 | 1996-11-12 | Resolution Pharmaceutical Inc. | Hydrazino-type N2 S2 chelators |
| US5662885A (en) | 1994-07-22 | 1997-09-02 | Resolution Pharmaceuticals Inc. | Peptide derived radionuclide chelators |
| US6333021B1 (en) | 1994-11-22 | 2001-12-25 | Bracco Research S.A. | Microcapsules, method of making and their use |
| DE4445065A1 (de) | 1994-12-07 | 1996-06-13 | Diagnostikforschung Inst | Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung |
| GB9502065D0 (en) | 1995-02-02 | 1995-03-22 | Nycomed Imaging As | Contrast media |
| US6500948B1 (en) | 1995-12-08 | 2002-12-31 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof |
| JP3795339B2 (ja) * | 1996-01-23 | 2006-07-12 | 塩野義製薬株式会社 | スルホン化されたアミノ酸誘導体およびそれを含有するメタロプロティナーゼ阻害剤 |
| ES2206689T3 (es) | 1996-10-28 | 2004-05-16 | Amersham Health As | Agentes de contraste. |
| WO1998018498A2 (en) | 1996-10-28 | 1998-05-07 | Marsden, John, Christopher | Improvements in or relating to diagnostic/therapeutic agents |
| ATE314097T1 (de) | 1996-10-28 | 2006-01-15 | Amersham Health As | Kontrastmittel |
| EP0973552B1 (en) | 1996-10-28 | 2006-03-01 | Amersham Health AS | Improvements in or relating to diagnostic/therapeutic agents |
| EP0991427A2 (en) | 1996-10-28 | 2000-04-12 | Marsden, John Christopher | Improvements in or relating to diagnostic/therapeutic agents |
| EP0983267B1 (en) | 1997-03-04 | 2005-01-26 | Pharmacia Corporation | Amidoaromatic ring sulfonamide hydroxamic acid compounds |
| DE19717904A1 (de) | 1997-04-23 | 1998-10-29 | Diagnostikforschung Inst | Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie |
| US5886142A (en) | 1997-05-20 | 1999-03-23 | Thomas Jefferson University | Radiolabeled thrombus imaging agents |
| US6245318B1 (en) | 1997-05-27 | 2001-06-12 | Mallinckrodt Inc. | Selectively binding ultrasound contrast agents |
| GB9712525D0 (en) | 1997-06-16 | 1997-08-20 | Nycomed Imaging As | Method |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| PL342009A1 (en) | 1998-02-04 | 2001-05-07 | Novartis Ag | Sulphonylamine derivatives capable to inhibit extracellular substance degrading metaloproteinases |
| RU2217418C2 (ru) | 1998-04-03 | 2003-11-27 | Санкио Компани, Лимитед | Сульфонамидное производное, лекарственное средство, способы лечения |
| US6093382A (en) | 1998-05-16 | 2000-07-25 | Bracco Research Usa Inc. | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
| US6800646B1 (en) | 1999-02-08 | 2004-10-05 | Pharmacia Corporation | Sulfamato hydroxamic acid metalloprotease inhibitor |
| WO2003000830A1 (en) | 1999-12-09 | 2003-01-03 | Texas Petrochemicals Lp | Low lead aviation gasoline blend |
| IT1315263B1 (it) | 1999-12-21 | 2003-02-03 | Bracco Spa | Composti chelanti,loro chelati con ioni metallici paramagnetici, loropreparazione ed uso |
| US7790144B2 (en) * | 2000-01-18 | 2010-09-07 | Mallinckrodt Inc. | Receptor-avid exogenous optical contrast and therapeutic agents |
| IT1317862B1 (it) | 2000-02-29 | 2003-07-15 | Bracco Spa | Coniugati di acidi biliari con chelati complessi di ioni metallici eloro uso. |
| KR20030005230A (ko) | 2000-03-21 | 2003-01-17 | 더 프록터 앤드 갬블 캄파니 | N-치환된 메탈로프로테아제 저해제를 함유하는 탄소환식측쇄 |
| MXPA01013326A (es) | 2001-02-14 | 2002-08-26 | Warner Lambert Co | Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz. |
| ITMI20011518A1 (it) | 2001-07-17 | 2003-01-17 | Bracco Imaging Spa | Leganti azotati multidentati capaci di complessare ioni metallici e loro uso in diagnostica e in terapia |
| US20060093552A1 (en) * | 2002-03-11 | 2006-05-04 | Molecular Insight Pharmaceuticals, Inc. | Technetium-and rhenium-bis(heteroaryl) complexes, and methods of use thereof |
| US7226577B2 (en) | 2003-01-13 | 2007-06-05 | Bracco Imaging, S. P. A. | Gastrin releasing peptide compounds |
| EP1592458A1 (en) * | 2003-02-10 | 2005-11-09 | GE Healthcare Limited | Diagnostic imaging agents with mmp inhibitory activity |
| US20080124270A1 (en) | 2003-12-23 | 2008-05-29 | Bracco Imaging S.P.A. | Compounds Useful as Metal Chelators |
| US7749485B2 (en) | 2004-06-03 | 2010-07-06 | Bracco Research S.A. | Liposomal assembly for therapeutic and/or diagnostic use |
| EP1765812B1 (en) | 2004-07-02 | 2009-04-29 | Bracco Imaging S.p.A | Contrast agents endowed with high relaxivity for use in magnetic resonance imaging (mri) which contain a chelating moiety with polyhydroxylated substituents |
| GB0421308D0 (en) | 2004-09-24 | 2004-10-27 | Amersham Plc | Enzyme inhibitor imaging agents |
| GB0428012D0 (en) * | 2004-12-22 | 2005-01-26 | Hammersmith Imanet Ltd | Radiolabelling methods |
| ITTO20060575A1 (it) * | 2006-08-02 | 2008-02-03 | Univ Pisa | Inibitori di zinco proteinasi tioaril sostituiti e loro usi |
| EP1972617A1 (en) * | 2007-03-19 | 2008-09-24 | Bracco Imaging, S.P.A. | Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors |
-
2008
- 2008-07-22 EP EP08160856A patent/EP2147684A1/en not_active Withdrawn
-
2009
- 2009-07-21 WO PCT/EP2009/059338 patent/WO2010010079A1/en not_active Ceased
- 2009-07-21 EP EP09800042.5A patent/EP2320954B1/en active Active
- 2009-07-21 CN CN200980128435.1A patent/CN102105174B/zh not_active Expired - Fee Related
- 2009-07-21 JP JP2011519144A patent/JP5619740B2/ja not_active Expired - Fee Related
- 2009-07-21 US US13/000,794 patent/US9480758B2/en not_active Expired - Fee Related
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1207734A (zh) * | 1995-12-08 | 1999-02-10 | 阿格罗尼制药公司 | 金属蛋白酶抑制剂,含有它们的药物组合物和其药物用途,其制备方法和中间体 |
| CN1214041A (zh) * | 1996-01-23 | 1999-04-14 | 盐野义制药株式会社 | 磺化的氨基酸衍生物及含有它的金属蛋白酶抑制剂 |
| US5985900A (en) * | 1997-04-01 | 1999-11-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| WO1999042433A1 (en) * | 1998-02-18 | 1999-08-26 | Inha University Foundation | Process for nitration of aromatic compounds using a non-acid type nitration process |
| WO1998039313A1 (en) * | 1998-03-04 | 1998-09-11 | Monsanto Company | Thioaryl sulfonamide hydroxamic acid compounds |
| CN1450915A (zh) * | 2000-02-15 | 2003-10-22 | 布里斯托尔-迈尔斯斯奎布药品公司 | 作为诊断剂中靶组分的基质金属蛋白酶抑制剂 |
| WO2003080042A1 (en) * | 2002-03-27 | 2003-10-02 | Shionogi & Co., Ltd. | Decomposition inhibitor for extracellular matrix of cartilage |
| CN1747749A (zh) * | 2003-02-10 | 2006-03-15 | 通用电气健康护理有限公司 | 具有mmp抑制活性的诊断造影剂 |
| CN1901894A (zh) * | 2003-11-14 | 2007-01-24 | 通用电气健康护理有限公司 | 抑制剂成像剂 |
| CN1913880A (zh) * | 2003-12-04 | 2007-02-14 | 惠氏公司 | 治疗adamts-5相关疾病的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US9480758B2 (en) | 2016-11-01 |
| CN102105174A (zh) | 2011-06-22 |
| JP5619740B2 (ja) | 2014-11-05 |
| EP2147684A1 (en) | 2010-01-27 |
| US20110117015A1 (en) | 2011-05-19 |
| WO2010010079A1 (en) | 2010-01-28 |
| EP2320954B1 (en) | 2019-09-04 |
| JP2011528688A (ja) | 2011-11-24 |
| EP2320954A1 (en) | 2011-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100539041B1 (ko) | 퍼플루오로알킬-함유금속착물및nmr진단에서의그의용도 | |
| US9409951B2 (en) | Integrin targeted synthetic ligands for diagnostic and therapeutic applications | |
| US11401262B2 (en) | Dimeric contrast agents | |
| US20050106100A1 (en) | Compounds containing matrix metalloproteinase substrates and methods of their use | |
| KR20040030825A (ko) | 마크로시클릭 금속 착물과 생체분자와의 콘쥬게이트 및nmr 진단 및 방사성진단 및 방사성치료에 사용하기위한 약제의 제조를 위한 그의 이용 | |
| JP5619740B2 (ja) | メタロプロテアーゼの選択的診断剤 | |
| US8231858B2 (en) | Diagnostic imaging agents with MMP inhibitory activity | |
| US20090297454A1 (en) | Perfluoroalkyl-Containing Complexes, Process For Their Production As Well As Their Use | |
| JP6087386B2 (ja) | 造影剤としてのn−アルコキシアミド抱合体 | |
| JP2009509915A (ja) | ペルフルオロアルキル含有錯体、ならびにnmr、x線および放射線診断、さらに放射線治療のための造影剤としてのその使用法 | |
| KR20080022588A (ko) | 영상화제로서의 히드라지드 컨쥬게이트 | |
| JP2010506862A (ja) | 過弗素化されたpeg基を有する金属キレート類、それらの製剤方法、及びそれらの使用 | |
| CA2243316C (en) | Metal complexes that contain perfluoroalkyl, process for their production and their use in nmr diagnosis | |
| US20040208828A1 (en) | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic acid and derivatives thereof, process for their production and use for the production of pharmaceutical agents | |
| MXPA06002312A (en) | Compounds containing matrix metalloproteinase substrates and methods of their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140702 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |